Registry on HIV-related lymphoma
Official title: Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group
Run by Rotkreuzklinikum München gGmbH · NCT05231135 · Data updated 2026-11-12
This study collects information from people with HIV-related lymphoma to see how they are treated and how well those treatments work.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Rotkreuzklinikum München gGmbH Academic / other |
| Drugs / interventions | cART |
| Locations | 6 sites (Munich, Select One Option and 5 other locations) |
| Status | Recruiting |
| Started | August 25, 2021 |
| Main results expected | August 31, 2024 |
| Study ends | August 31, 2029 |
| Registry record updated | April 6, 2023 |
| Trial ID | NCT05231135 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have a confirmed diagnosis of HIV and either non-Hodgkin lymphoma or Hodgkin lymphoma.
✕Probably not a fit
Patients diagnosed with HIV more than three months after their lymphoma diagnosis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study collects data on patients with HIV-associated lymphoma to analyze their characteristics, treatment approaches, and outcomes. It includes both retrospective and prospective data from individuals diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma since January 1, 2010. The treatment choices will adhere to established national and international guidelines, and data will be pseudonymized for confidentiality. The central data management is conducted at Red Cross Hospital in Munich, Germany.
Why it matters
Potential benefit: If successful, this study could improve understanding of treatment outcomes for patients with HIV-related lymphoma, leading to better management strategies.
How similar studies have gone: Other studies have explored HIV-related lymphomas, but this registry approach may provide novel insights into treatment outcomes in the context of combination antiretroviral therapy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma * HIV-infection at time of lymphoma diagnosis * Lymphoma diagnosis since 01.01.2010 * Adult patients ≥ 18 years * Written informed consent Exclusion Criteria: * HIV-diagnosis \> 3 months after the diagnosis of malignant lymphoma * Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)
Where it's running
-
Red Cross Hospital Munich
Munich, Select One Option, Germany Recruiting -
University Hospital Cologne
Cologne, Germany Recruiting -
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain Recruiting -
Hospital Universitario de Salamanca
Salamanca, Spain Recruiting -
Amsterdam University Medical Centers
Amsterdam, Netherlands Not yet recruiting -
University Hospital of Wales
Cardiff, United Kingdom Not yet recruiting
Study contacts
- Study coordinator: Marcus Hentrich, MD
- Email: marcus.hentrich@swmbrk.de
- Phone: +49 89 1303 4372
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Optimizing HIV Therapy for AIDS-Related Lymphoma Patients
This study tests whether long-acting HIV medicines given during lymphoma treatment work better at keeping the virus suppressed than standard oral therapy in adults with AIDS-related lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.